ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2022
AD-associated CSF biomolecular changes are attenuated in KL-VS heterozygotes.
Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 9 citations in OpenAlex.
- KLOTHO-VS heterozygosity, α-klotho protein levels and cognitive performance in Alzheimer's disease.Alzheimer's research & therapy · 2025Article
- Associations of KLOTHO-VS heterozygosity and α-Klotho protein with cerebrospinal fluid Alzheimer's disease biomarkers.Journal of Alzheimer's disease : JAD · 2025Article
- Association between Klotho levels in cerebrospinal fluid and choroid plexus enlargement in neurodegeneration.Frontiers in aging neuroscience · 2025Article
- Amyloid-β positivity is less prevalent in cognitively unimpairedJournal of Alzheimer's disease : JAD · 2024Article
- Biological mechanisms of resilience to tau pathology in Alzheimer's disease.Alzheimer's research & therapy · 2024Article
- KLOTHO KL-VS heterozygosity is associated with diminished age-related neuroinflammation, neurodegeneration, and synaptic dysfunction in older cognitively unimpaired adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- AD-associated CSF biomolecular changes are attenuated in KL-VS heterozygotes.Alzheimer's & dementia (Amsterdam, Netherlands) · 2022Article
- More fit KL-VS heterozygotes have more favorable AD-relevant biomarker profiles.Alzheimer's & dementia (New York, N. Y.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 3 countries.
Funding
Abstract
Introduction: Dementia as an inevitable aging consequence has been challenged and underscores the need for investigations of the factors that confer resilience. We examine whether the functionally advantageous KL-VS variant of the putative aging suppressor Methods: Trajectories of change in memory and executive function ( Results: Memory and executive function declined ( Discussion: KL-VS heterozygosity may confer resilience to AD-associated biomolecular changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.